How to Navigate Ecosystem Connect NEWDistinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats
LASER - a Phase 2 Trial of 177Lu-PSMA-617 as Systemic Therapy for Renal Cell Carcinoma
Description:
This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC).
Sponsor:
Dana-Farber Cancer Institute
Contacts:
Praful Ravi, MB BCHir, MRCPpraful_ravi@dfci.harvard.edu
617-632-3466
Government Study Link:
NCT06964958 - Click here to see study onClinicalTrials.gov
177Lu-PSMA-617
Isotope(s):
Target(s):
- PSMA
Ligand: Small Molecules
Chelator: DOTA
